Teva Asks Supreme Court For Stay On MS Drug Patent Ruling

Law360, Los Angeles (November 5, 2013, 6:39 PM EST) -- Teva Pharmaceuticals USA Inc. on Monday asked the U.S. Supreme Court to stay a Federal Circuit decision that invalidated several patents covering Copaxone, claiming the ruling would sap the multiple sclerosis drug's annual sales of nearly $3 billion.

Teva said the Federal Circuit decision, which cleared the way for Mylan Inc. and Sandoz Inc. to launch generic versions of Copaxone in May 2014 instead of September 2015, would cause irreparable harm to Teva.

The July ruling that five of Teva's nine Copaxone patents were invalid due...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.